Operating Cash Flow
United Therapeutics Operating Cash Flow increased by 33.8% to $463.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.5%, from $461.20M to $463.30M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 27.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
Detailed definition
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Peer comparison
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operatingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $148.20M | $185.60M | $174.60M | $288.70M | $127.00M | $258.60M | $128.20M | $374.80M | $106.30M | $346.20M | $150.70M | $376.50M | $232.20M | $377.20M | $341.20M | $461.20M | $191.70M | $562.10M | $346.20M | $463.30M |
| QoQ Change | — | +25.2% | -5.9% | +65.3% | -56.0% | +103.6% | -50.4% | +192.4% | -71.6% | +225.7% | -56.5% | +149.8% | -38.3% | +62.4% | -9.5% | +35.2% | -58.4% | +193.2% | -38.4% | +33.8% |
| YoY Change | — | — | — | — | -14.3% | +39.3% | -26.6% | +29.8% | -16.3% | +33.9% | +17.6% | +0.5% | +118.4% | +9.0% | +126.4% | +22.5% | -17.4% | +49.0% | +1.5% | +0.5% |
Operating Cash Flow at Other Companies
Frequently Asked Questions
- What is United Therapeutics's operating cash flow?
- United Therapeutics (UTHR) reported operating cash flow of $463.30M in Q1 2026.
- How has United Therapeutics's operating cash flow changed year-over-year?
- United Therapeutics's operating cash flow increased by 0.5% year-over-year, from $461.20M to $463.30M.
- What is the long-term trend for United Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), United Therapeutics's operating cash flow has grown at a 27.1% compound annual growth rate (CAGR), from $598.20M to $1.56B.
- What does operating cash flow mean?
- The amount of cash a company generates from its regular business activities.